News >

Novel Radionuclide Treatment Shows Promise in mCRPC

Jason Harris
Published: Friday, May 11, 2018

Michael S. Hofman, MBBS

Michael S. Hofman, MBBS
Radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival (PFS) in men with progressive metastatic castrate-resistant prostate cancer (mCRPC) compared with previous results with another radiopharmaceutical, radium-223 (Ra-223; Xofigo), according to updated results from the phase II LuPSMA study published in The Lancet Oncology.

In LuPSMA, the median PSA PFS was 7.6 months (95% CI, 6.3-9.0) and 27 (90%) of 30 men experienced PSA progression. The median overall survival (OS) was 13.5 months (95% CI, 10.4-22.7) and 22 (73%) men had died by the November 2017 data cutoff.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication